Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200405 | 0.76 | ALDH1A1 (0.34) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9752617 | 0.73 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL2984138 | 0.73 | ALDH1A1 (0.34) | ALDH1A1ALOX15 | |
| SCHEMBL9054019 | 0.71 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL235785 | 0.71 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL38652375 | 0.71 | ALDH1A1 (0.39) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3395531 | 0.70 | ALDH1A1 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2329267 | 0.70 | ALDH1A1 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6682528 | 0.70 | ALDH1A1 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL27679077 | 0.69 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2173698-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF RENIN INHIBITORS SUCH AS ALISKIREN | Novartis Ag (CH) | 2010-04-14 | — | — | EP | disclosed |
| WO-2008155338-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | CYP1B1, CYP3A7, CYP2F1 | CA12 1336/4885CA1 2853/4885CA2 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.